Olivier De Henau, MD
About Olivier De Henau, MD
Olivier De Henau, MD, is the Early Clinical Development Lead at Bristol-Myers Squibb and Medical Director at iTeos Therapeutics SA, with a focus on improving immunotherapy for advanced cancer patients.
Title
Olivier De Henau, MD, serves as the Early Clinical Development Lead. He is currently affiliated with iTeos Therapeutics SA as Medical Director and with Bristol-Myers Squibb as Early Clinical Development Lead.
Current Roles
Olivier De Henau is actively engaged at iTeos Therapeutics SA, where he holds the position of Medical Director. He also works with Bristol-Myers Squibb in the role of Early Clinical Development Lead. He operates in dual locations, Boston, Massachusetts, and Brussels, Belgium, focusing on clinical development and immunotherapy.
Memorial Sloan Kettering Cancer Center Experience
From 2014 to 2016, Olivier De Henau worked as a Research Fellow at the Ludwig Center for Cancer Immunotherapy, part of Memorial Sloan Kettering Cancer Center in Greater New York City. His responsibilities included advancing research in cancer immunotherapy.
Institut Jules Bordet Tenure
Olivier De Henau served at Institut Jules Bordet in two roles: Clinical Fellow in Medical Oncology and Hematology from 2011 to 2013, and Assistant-Attending Physician from 2013 to 2015. His work focused on enhancing patient care in oncology and hematology.
Education and Early Career
Olivier De Henau completed his Doctor of Medicine (M.D.) degree at Université libre de Bruxelles, where he studied from 1995 to 2002. He subsequently held multiple roles including Clinical Fellow in Internal Medicine and Research Fellow in various medical fields, demonstrating a solid foundation in medical training and research.